ArticleJournal of orthopaedic case reports2024
Fibroadipose Vascular Anomaly [FAVA] - A Distinct Entity and Not Just a Malformation!
Article in Journal of orthopaedic case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Fibroadipose vascular anomaly (FAVA) was described in 2014 as a distinct entity characterised by intramuscular replacement with fibro fatty tissue along with complex vascular malformation, phelbectesia, venous thrombosis and lymphatic involvement. Somatic mutations in the PIK3CA gene are detected in most lesions which diagnosed the FAVA in our report and occurrence of this mutation seems to be sporadic. Case Report: Common presentation is a painful intramuscular swelling in young women - as was the presentation here in an 11 year girl with the swelling of the right thigh. Imaging features, phleboliths and long standing history of an intramuscular malformation in the young girl that was recalcitrant to treatment at previous attempts led us towards the suspicion of a fibro adipose vascular anomaly. Conclusion: Surgery with en-bloc mass excision is recommended for good long term curative option for reducing pain and regaining movements. FAVA is a rare, but specific vascular anomaly that is often misdiagnosed with other intramuscular vascular malformations and therefore poses significant management challenges. It is imperative that clinicians have a thorough understanding of FAVA in order to provide proper diagnosis and treatment referrals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.